In this Issue:
This review discusses published clinical trial evidence for the use of Aflibercept, an anti-VEGF agent that is indicated for adults with neovascular age-related macular degeneration (AMD). Aflibercept is fully funded under the Pharmaceutical Benefits Schedule (Authority required).
Independent commentary has been provided by Dr Simon Chen, an Ophthalmologist and Retinal Specialist at Vision Eye Institute, Sydney and a Conjoint Senior Lecturer at the University of New South Wales.
Please login below to download this issue (PDF)